Human protein slows muscle damage in muscular dystrophy miceDecember 28th, 2010 - 6:08 pm ICT by ANI
Washington, Dec 28 (ANI): A new study has found that a novel potential therapy based on a natural human protein significantly slows muscle damage and improves function in mice who have the same genetic mutation as boys with the most common form of muscular dystrophy.
Boys suffering from Duchenne Muscular Dystrophy are unable to produce a protein called dystrophin that keeps muscles strong.
“This (the study) is aimed at getting a therapy that will meaningfully improve the condition of patients,” said Justin Fallon, professor of neuroscience at Brown University and the senior author of the paper.
“This is an important step along that path,” he added.
The key protein Biglycan restores the muscle-strengthening presence of a protein called utrophin, which is normally prevalent only in very young children.
Utrophin still exists in adults, but in fewer places and not where it can help muscular dystrophy sufferers who cannot produce dystrophin, which keeps adult muscles strong.
In experiments described in the paper, Fallon’s team showed that biglycan delivered to the bloodstream draws utrophin to the cellular membranes of muscle cells.
Much as utrophin does when it is present in foetuses, infants and toddlers, the protein works to help the cells build and retain their strength.
In more recent tests using an improved formulation of biglycan, Fallon said the team has seen that figure rise to 50 percent in some muscles, meaning that mice treated with biglycan are holding on to more of their function for a longer time.
He said the effects of treatment with biglycan lasted through months of testing.
Several basic tests for side effects during that timeframe, such as kidney and liver function, did not indicate any harm from the therapy.
With the efficacy of biglycan apparent in the mouse model of Duchenne Muscular Dystrophy, the researchers are eager to see if it can improve the lives of thousands of children.
“The next big step is testing in humans,” said Fallon.
The study is currently published online in the Proceedings of the National Academy of Sciences. (ANI)
- New drug offers hope to muscular dystrophy patients - Oct 21, 2009
- First clinical trial of gene therapy offers muscular dystrophy clues - Oct 07, 2010
- Gene responsible for Duchenne muscular dystrophy can be repaired - Apr 16, 2010
- New therapy shows promise in treating muscular dystrophy - May 27, 2009
- New discovery may help develop therapies for childhood muscular dystrophy - Aug 04, 2009
- Protein that can ameliorate severe muscular dystrophy unveiled - Nov 03, 2008
- Manipulating muscle stem cells could treat muscular dystrophy - Oct 10, 2010
- Gene therapy shows promise in muscular dystrophy battle - Nov 12, 2009
- Novel discovery may pave way for new muscular dystrophy therapies - Jul 17, 2009
- Novel discovery could help in early identification of muscular dystrophy - Jun 17, 2009
- Gene therapy for muscular dystrophy comes closer to reality - Feb 27, 2009
- Burning more sugar drives super athleticism - Dec 01, 2011
- Protein modification involved in muscular dystrophy, cancer discovered - Jan 01, 2010
- Enzyme behind muscular dystrophy unveiled - Dec 09, 2008
- Tarantula venom could help treat muscular dystrophy - Dec 31, 2009
Tags: bloodstream, brown university, cellular membranes, dystrophin, efficacy, fallon, genetic mutation, human protein, infants and toddlers, kidney, liver function, mice, mouse model, muscle cells, muscle damage, muscles, muscular dystrophy, neuroscience, timeframe, utrophin